Information Provided By: 
Fly News Breaks for March 16, 2015
RPRX
Mar 16, 2015 | 14:54 EDT
Brean Capital noted that Repros submitted the NDA for Androxal to the FDA in February and the firm expects the NDA to be accepted next month. Brean believes acceptance of the NDA can be a "meaningful" catalyst for Repros since bears think the FDA doesn't wish to treat patients lacking an anatomical reason for low testosterone. Brean said its expects the FDA to approve Androxal for secondary hypogonadism driven by weight gain next year and maintains its Buy rating and $41 price target on Repros shares.
News For RPRX From the Last 2 Days
There are no results for your query RPRX
